• Veritas takes part with a stand where it will exhibit its entire portfolio of perinatal medicine, from myPrenatal GenomeScreeen, the new generation of non-invasive prenatal testing (NIPT), to the most comprehensive neonatal genetic screening on the market, and PregnancyLoss, a test that enables the possible underlining genetic cause of a miscarriage.

Veritas Intercontinental attends this year’s edition of the World Congress of Perinatal Medicine, WCPM 2023, held at the Milan Convention Centre, from May 7th to 10th, 2023. 

Veritas, a leader in perinatal medicine and one of the sector’s main providers in Europe, takes part with a stand where it will display myPrenatal, the new generation of non-invasive prenatal testing (NIPT), which is revolutionizing this type of tests in genomic terms; myPrenatalWES, a revolutionary exome sequencing test suitable for pregnancies at risk of presenting a genetic alteration; PregnancyLoss, which enables the possible underlying genetic causes of pregnancy loss; and myNewborn, which helps to find out the risk of the newborn developing 390 diseases of genetic origin and with the onset occurring during the first years of life.

The Congress brings together more than 2,500 experts in the fields of gynecology and obstetrics who will share the latest developments in research and clinical care in the field of perinatal medicine. 

About the congress

The world congress is organized by the World Association of Perinatal Medicine (WAPM) in coordination with the Perinatal Medicine Foundation (PMF) and in collaboration with the Italian Society of Ultrasound in Obstetrics and Gynecology (SIEOG).

The congress will feature meetings of professors from more than 100 countries around the world who will give presentations on the latest advances in medicine, presenting topics of interest in areas of obstetrics, gynecology, nursing, fertility, reproductive health, neonatology, public health and modern diagnostic technologies and interventions, developing solutions for better care and management in perinatology, appropriate to each region and country, whose ultimate goal is to improve health and the maternal-neonatal morbidity and mortality rate.

About Veritas

At Veritas, we apply science and our global resources to bring genetic and genomic diagnostics to people to extend and significantly improve their lives. Our global portfolio includes preventive medicine, perinatal medicine, and genomic diagnostic services.

In March 2022 Veritas announced that it was becoming part of LetsGetChecked, a global healthcare solutions company based in Dublin and New York.

In keeping with our responsibility as a leading biotechnology company, we collaborate with healthcare providers, governments, and local communities to support and expand access to genetic and genomic medicine reliably and affordably around the world.